Genpact launches an Artificial Intelligence (AI)-based solution to usher in a new era of drug safety automation. <\/p>\n
Genpact's Pharmacovigilance Artificial Intelligence (PVAI) will be the life sciences industry's first fully-integrated, end-to-end adverse event (AE) processing solution, leveraging intelligent automation to not only reduce the effort of processing adverse events, but also to enable an AI-driven level of real-time predictive analytics and actionable insight not previously possible. <\/p>\n
As life sciences companies face escalating AE volumes for their products and increasing pressure to improve quality and compliance while reducing costs, they are looking for breakthrough solutions to help them transform their pharmacovigilance operations. <\/p>\n
Genpact's PVAI offering brings together and integrates optical character recognition, robotic process automation, natural language processing, and machine learning technologies to automatically extract and code AE data from unstructured and semi-structured source documentseliminating manual workflow, saving pharmaceutical companies significant time and resources, and helping to establish a scalable PV operating model. The solution continuously builds predictive insights as more and more AE goes through it over time. <\/p>\n
\"Industry leaders have stated that the current manually-intensive approach to AE processing is simply not sustainable and needs an innovative approach. Through robust pilot testing with clients, our new PVAI solution has proven that the vast majority of case processing can be successfully automated in a fraction of the time and cost,\"said Balkrishan 'BK' Kalra, senior vice president and business leader, Consumer Goods, Retail, Life Sciences and Healthcare, Genpact. \"We continue to invest in PVAI and are excited to bring this holistic, unique and market-leading, AI-driven digital proposition to the industry.\" <\/p>\n
As part of its investments in PVAI, Genpact recently acquired the assets and team of November Research Group (NRG), aBerkeley, CA-basedprovider of product vigilance software. The transaction added NRG's domain expertise and fully-featured pharmacovigilance Software-as-a-Service, contributing to PVAI's approach to automating drug safety operations in the life sciences industry. Terms of the deal were not disclosed. <\/p>\n
Genpact currently serves global life sciences companies, helping pharmaceutical and medical devices companies pursue growth, achieve cost reduction, increase speed to market, and improve regulatory compliance by providinga range of digital solutions, analytics services, and business process transformation expertise. Genpact has alife sciencesregulatory servicesbusiness stemming from its acquisition of Pharmalink in 2014. <\/p>\n
(Source: PR Newswire) <\/p>\n
<\/p>\n
Go here to read the rest: <\/p>\n
Genpact Launches AI-based Drug Safety Automation Program - Pharmaceutical Processing<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Genpact launches an Artificial Intelligence (AI)-based solution to usher in a new era of drug safety automation. Genpact's Pharmacovigilance Artificial Intelligence (PVAI) will be the life sciences industry's first fully-integrated, end-to-end adverse event (AE) processing solution, leveraging intelligent automation to not only reduce the effort of processing adverse events, but also to enable an AI-driven level of real-time predictive analytics and actionable insight not previously possible. Continue reading